

Index

- acetylcholinesterase inhibitors. *See also specific inhibitors*
 for ADAD, 11
 for dementia following stroke, 114
 for LBD, 97–99
 for PCA, 61, 66–67
 for typical AD, 15
 for VCI, 118
- active reserve, 20
- AD. *See* Alzheimer disease
- ADAD. *See* autosomal dominant AD
- agrammatism, in non-fluent/agrammatic PPA, 72
- alexia without agraphia
 autopsy, 79–80
 clinical history and main complaint, 78
 diagnosis, 78
 discussion, 80–81
 examination, 78
 family history, 78
 follow-up, 78–79
 general history, 78
- alpha-synuclein
 in LBD, 97–99
 in MSA-P, 103
- ALS-FTD. *See* amyotrophic lateral sclerosis with FTD
- Alzheimer disease (AD). *See also* atypical AD; autosomal dominant AD; typical AD
 clinical history and main complaint, 26
 cognitive reserve and, 18–21
 diagnosis, 27
 diagnostic criteria, 166–167
 diagnostic workup, 1–5
 discussion and take-home messages, 27–29
 examination, 26
 family history, 26
 follow-up, 26–27
 frontal variant, 169
 general history, 26
 iNPH compared with, 129–131
 laboratorial testing and imaging, 26–27
 logopenic PPA with, 75–77
 NIA-AA diagnostic criteria for, 27–29
- VCI concomitant with, 116–123
 young-onset dementia, 2–3
- amino (NH₂)-terminal of α -enolase (NAE), 124–126
- amyloid pathology
 in ADAD, 10–12
 biomarkers of, 2–5
 without clinical manifestation, 18–21
 tau pathology in absence of, 23–24
- amyloid PET scan
 ADAD, 10–12
 ARIA in AD, 26–27
 cognitive reserve, 18–21
 diagnostic workup using, 2–4
 NFTPD and PART, 22–24
 typical AD, 15–16
- amyloid-lowering agents, adverse events with, 26–28
- amyloid-related imaging abnormalities (ARIA)
 clinical history and main complaint, 26
 diagnosis, 27
 discussion and take-home messages, 27–29
 examination, 26
 family history, 26
 follow-up, 26–27
 general history, 26
 laboratorial testing and imaging, 26–27
- amyotrophic lateral sclerosis with FTD (ALS-FTD)
 clinical features, 39–40
 clinical history and main complaint, 36
 diagnosis, 38
 discussion, 39–41
 epidemiology and genetics, 39
 examination, 36–37
 family history, 36
 follow-up, 38–39
 future directions, 41
 general history, 36
 investigations, 40–41
 management, 41
 pathology, 39
 special studies, 37–38
- angular gyrus syndrome, 80–81
- anosognosia
 in FTLD, 57
 in typical AD, 15
- anti-amyloid therapy, adverse events with, 26–28
- anti-NMDA receptor encephalitis. *See* NMDA-receptor antibody positive limbic encephalitis
- anti-thyroglobulin (TG) antibodies, 124–125
- anti-thyroid peroxidase (TPO) antibodies, 124–125
- AOS. *See* apraxia of speech
- aphasia. *See* primary progressive aphasia
- apolipoprotein E4 polymorphism, 26–27
- apraxia of speech (AOS), 72. *See also* primary progressive AOS
- ARIA. *See* amyloid-related imaging abnormalities
- artistic talent
 semantic PPA with emergence of, 44, 89–94
- atypical AD. *See also* posterior cortical atrophy
 MAPT mutation, 44–48
 PCA as, 61, 66
- atypical dementia
 biomarkers of, 2–5
- auditory comprehension, in non-fluent/agrammatic PPA, 69–70, 72
- autoimmune limbic encephalitis
 HE, 124–126
 NMDA-receptor antibody positive, 120–123
- autonomic dysfunction, in MSA-P, 101–103
- autopsy
 alexia without agraphia in Pick's disease, 79–80
 CJD, 133
 GRN mutations, 51–52
 MAPT mutations, 46–48
- autosomal dominant AD (ADAD)
 clinical history and main complaint, 10
 diagnosis, 11

- discussion and take-home messages, 11–12
 examination, 10
 family history, 10
 follow-up, 11
 general history, 10
 laboratorial assessment and imaging, 10–11
 axial rigidity, in PSP, 92–93
 Aβ1–42, 4, 16
- Balint's syndrome, 65
 basal ganglia calcification. *See* idiopathic basal ganglia calcification
 behavioural variant FTD (bvFTD)
 C9orf72 mutations with, 39–40
 CHMP2B mutations with, 57
 clinical heterogeneity in, 141–142
 clinical history and main complaint, 30
 CSF analysis, 31
 diagnosis, 31
 discussion, 32–34
 family history, 54
 follow-up, 31–32
 general history, 30
 genetic analysis, 31–33
 neuroimaging, 31, 33
 neurological exam, 68
 neuropsychological and functional assessment, 30–31
 RtvFTD compared with, 140–144
 behavioural/dysexecutive variant AD
 diagnostic criteria, 169
 Benson's Syndrome
 clinical history and main complaint, 59
 diagnosis, 60
 discussion, 61
 examination, 59
 family history, 59
 follow-up, 60–61
 general history, 59
 special studies, 59–61
 take-home messages, 62
 beta amyloid, 4, 16
 biomarkers. *See also* CSF analysis; magnetic resonance imaging; positron emission tomography
 of atypical dementia, 2–5
 without clinical manifestation of AD, 18–21
 diagnostic workup using, 1–5
 NIA-AA AD staging with, 27–29
 of typical AD, 16
 brain reserve, 20
 bvFTD. *See* behavioural variant FTD
- C9orf72* mutation. *See* chromosome 9 open reading frame 72 mutation
 calcifications. *See* idiopathic basal ganglia calcification
 cancer, behavioral changes and cognitive symptoms in, 120, 122
 care planning
 case outcome, 7–8
 diagnosis, 7
 discussion, 7–8
 examination, 6–7
 history, 6
 special studies, 7
 take-home message, 9
 CBD. *See* cortico-basal degeneration
 Cerebrolysin, 114–115
 cerebrovascular disease (CVD)
 biomarkers of, 3
 dementia following stroke, 112–115
 evaluation of, 117–118
 in NFTPDP and PART cases, 24
 small vessel, 116, 118
 VCI with concomitant AD, 116–119
 ceruloplasmin, 106–108
 charged multivesicular body protein 2B (*CHMP2B*) mutation, 33
 clinical history, 54
 complaint, 54
 diagnosis, 55–56
 discussion and take-home messages, 57
 examination, 54–55
 family history, 54
 follow-up, 56
 general history, 54
 chelating treatment, 106, 108
CHMP2B mutation. *See* charged multivesicular body protein 2B mutation
 chromosome 9 open reading frame 72 (*C9orf72*) mutation, 33
 clinical features, 39–40
 clinical history and main complaint, 36
 diagnosis, 38
 discussion, 39
 epidemiology and genetics, 39
 examination, 36–37
 family history, 36
 follow-up, 38–39
 future directions, 41
 general history, 36
 investigations, 40–41
 management, 41
 neurodegenerative disorders associated with, 39–40
 pathology, 39
 special studies, 37–38
- CJD. *See* Creutzfeldt-Jakob disease
 clinical practice, dementia recognition in, 6–7
 clozapine, 110–111
 cognitive assessment
 ADAD, 10
 ALS-FTD, 36–37
 ARIA in AD, 26–27
 atypical dementia, 48
 Benson's Syndrome, 59
 bvFTD, 30–31
 CJD, 132
 cognitive reserve, 18
 dementia following stroke, 112
 GRN mutations, 50
 IBGC, 149–150
 iNPH, 128
 LBD, 96
 logopenic PPA, 74–75, 77
 MAPT mutations, 45
 MSA-P, 101
 NFTPDP, 14, 22
 PCA with logopenia, 64
 PD, 110
 PSP, 92
 RtvFTD, 140
 semantic PPA, 84–85
 typical AD, 14
 cognitive reserve
 case history, 18
 clinical and cognitive assessments, 18
 diagnosis, 19
 discussion, 19
 family history, 18
 general history, 18
 medical history, 18
 MRI and PET acquisitions, 18–21
 computed tomography (CT)
 IBGC, 150
 iNPH, 129
 continuous external lumbar CSF drainage, 129
 copper, in Wilson's disease, 106–107
 cortico-basal degeneration (CBD), 155
 corticosteroids
 for HE, 125–126
 for NMDA-receptor antibody positive limbic encephalitis, 121–122
 cotton wool amyloid plaques (CWP), 10–12
 Creutzfeldt-Jakob disease (CJD)
 autopsy, 133
 clinical history, 132
 diagnosis, 133–135
 diagnostic criteria for, 153–154
 discussion, 133
 examination, 132
 familial, 139

Index

- Creutzfeldt-Jakob disease (CJD) (cont.)
 follow-up, 133
 general history, 132
 patient and family support in, 134–135
 special studies, 132–133
 sporadic, 133
- CSF analysis
 biomarkers analyzed in, 3–5
 bvFTD, 31
 CJD, 133
 diagnostic workup using, 2
 LBD, 99
 logopenic PPA, 75–77
 NMDA-receptor antibody positive
 limbic encephalitis, 120–122
 non-fluent/agrammatic PPA, 70–73
 typical AD, 16
- CSF-related dementia
 auxiliary examinations, 128–129
 case history, 127
 cognitive impairment in, 127–128
 diagnosis and differential diagnoses, 129–131
 discussion, 127–128
 follow-up, 130–131
 gait disturbance in, 127–128
 quantitative evaluation of clinical manifestations, 128
 treatment, 130–131
 urinary incontinence in, 127–128
- CT. *See* computed tomography
- CVD. *See* cerebrovascular disease
- CWP. *See* cotton wool amyloid plaques
- decision making capacity, 6–9
- depression, FTLT compared with, 54–55, 57
- diagnostic workup
 clinical history, 1
 complaint, 1
 diagnosis, 2
 discussion and take-home messages, 2–5
 examination, 1
 family history, 1
 general history, 1
 laboratory testing and imaging, 2
- L-3,4-dihydroxyphenylalanine. *See* levodopa
- donepezil
 for typical AD, 14–15
 for VCI, 118
- electroencephalogram (EEG)
 CJD, 132, 134
 HE, 124–125
 NMDA-receptor antibody positive
 limbic encephalitis, 120
- encephalitis
 HE, 124–126
 NMDA-receptor antibody positive, 120, 122
- essential thrombocytosis (ET), 113
- Evans index, 129
- FACT. *See* Frailty Assessment for Care Planning Tool
- Fahr's disease. *See* idiopathic basal ganglia calcification
- familial Creutzfeldt-Jakob disease (fCJD), 139
- fCJD. *See* familial Creutzfeldt-Jakob disease
- FDG-PET scan
 ADAD, 10–12
 C9orf72 mutations, 37–38, 40–41
 CHMP2B mutations, 54–56
 cognitive reserve, 18–21
 diagnostic workup using, 2–4
 IBGC, 149–151
 LBD, 96–99
 NFTPD and PART, 23–24
 non-fluent/agrammatic PPA, 70–71
 PCA with logopenia, 64–65
 PSP, 93, 110
 typical AD, 14–16
- FFI. *See* fatal familial insomnia
- fluid attenuated inverse recovery (FLAIR), 2–3
 ADAD, 10–11
 ARIA in AD, 26–28
- fluid biomarkers, 2–5. *See also* CSF analysis
- Frailty Assessment for Care Planning Tool (FACT), 6–8
- frontal variant AD (fvAD)
 diagnostic criteria, 169
- frontotemporal dementia (FTD). *See also* primary progressive aphasia
 behavioural variant, 30–34, 39–40, 57, 140–144
 C9orf72 mutations, 36–41
 CHMP2B mutations, 54–57
 clinical heterogeneity in, 140–141
 diagnostic criteria, 32–33, 168–169
 gene mutations in, 33
 GRN mutations, 49–52
 MAPT mutations, 44–48
 Pick's disease, 78–81, 172
 right temporal variant, 140–144
- frontotemporal lobar degeneration (FTLD), 140–141
- FTD. *See* frontotemporal dementia
- FTLD. *See* frontotemporal lobar degeneration
- fvAD. *See* frontal variant AD
- gait disturbance
 in ADAD, 10
- gait disturbance, in iNPH, 127–128
- galantamine, 118
- genetics
 ALS-FTD, 39
 bvFTD, 31, 33
 dementia following stroke, 113
 FTLT with TDP-43 inclusions, 52
 multiple system tauopathy with dementia, 46–47
 PSP, 93
 RtvFTD, 143
- Gerstmann's syndrome, 65
- Gerstmann-Sträussler-Scheinker disease (GSS), 10–12
- glucose PET scan. *See* FDG-PET scan
- GRN mutation. *See* progranulin mutation
- GSS. *See* Gerstmann-Sträussler-Scheinker disease
- hallucinations
 in LBD, 96–99
 in PD, 109–111
- Hashimoto's encephalopathy (HE)
 clinical history, 124
 diagnosis and treatment, 125
 discussion, 125–126
 examination, 124
 special studies, 124–125
- hippocampal volume, 3
- homonymous hemianopsia, 66
- hydrocephalus. *See* idiopathic normal pressure hydrocephalus
- hypertension, 119
- idiopathic basal ganglia calcification (IBGC)
 clinical history, 149
 diagnosis, 150
 discussion and take home messages, 150–151
 examination, 149–150
 family history, 149
 follow-up, 150
 general history, 149
- idiopathic normal pressure hydrocephalus (iNPH)
 auxiliary examinations, 128–129
 case history, 127
 cognitive impairment in, 127–128
 diagnosis and differential diagnoses, 129–131
 discussion, 127–128
 follow-up, 130–131
 gait disturbance in, 127–128
 quantitative evaluation of clinical manifestations, 128

- treatment, 130–131
 urinary incontinence in, 127–128
 imaging biomarkers, 2–5. *See also*
 magnetic resonance imaging;
 positron emission tomography
 iNPH. *See* idiopathic normal pressure
 hydrocephalus
- JAK2 V617F mutation, 113
- Kayser-Fleischer rings, 105, 107
- language assessment. *See* speech and
 language assessment
 language deficits
 in logopenic PPA, 75–76
 in non-fluent/agrammatic PPA, 68–73
 in PCA, 66
 in Pick's disease, 78–79, 81
 in semantic PPA, 84–91
 large-volume lumbar puncture, 129
 LBD. *See* Lewy body dementia
 LE. *See* limbic encephalitis
 levodopa
 in LBD, 99
 in MSA-P, 101–103
 in PD, 109–110
 Lewy body dementia (LBD)
 case report, 96–97
 diagnosis, 96–97
 diagnostic criteria, 162
 discussion, 98–99
 treatment and follow-up, 97–98
 limbic encephalitis (LE)
 HE, 124–126
 NMDA-receptor antibody positive,
 120, 122
 liver dysfunction, in Wilson's disease,
 105–108
 logopenia associated with PCA
 case history, 64
 cognitive examination, 64
 diagnosis, 65
 discussion, 65–67
 follow-up, 65
 paraclinical workup, 64–65
 physical examination, 64
 logopenic PPA (PPA-L), 71–72
 clinical consultation and
 neurological examination, 74
 clinical history and main complaint, 74
 cognitive and functional evaluations,
 74–75, 77
 diagnosis, 76
 discussion, 76
 family history, 74
 general history, 74
 laboratory tests and neuroimaging
 results, 75–77
- PCA compared with, 66
 speech and language assessment, 75
 lumbar puncture. *See also* CSF analysis
 large-volume, 129
- magnetic resonance imaging (MRI)
 ADAD, 10–11
 ARIA in AD, 26–28
 bipolar disorder, 120
 bvFTD, 31, 33
 C9orf72 mutations, 37–38, 40–41
 CJD, 132–134
 cognitive reserve, 18–21
 dementia following stroke, 112–114
 diagnostic workup using, 2–3
 HE, 124–125
 IBGC, 149–151
 iNPH, 129
 LBD, 96
 logopenic PPA, 75–77
 MAPT mutations, 45
 MSA-P, 103
 NFTPD and PART, 22–24
 NMDA-receptor antibody positive
 limbic encephalitis, 120–121
 non-fluent/agrammatic PPA, 70–73
 PSP, 93, 110
 RtvFTD, 140–141, 143–144
 semantic PPA, 85–86
 semantic PPA with artistic creativity,
 89
 typical AD, 15–16
 VCI with concomitant AD, 116
 Wilson's disease, 106, 108
 MAPT mutation. *See* microtubule-
 associated protein tau mutation
 MCI. *See* mild cognitive impairment
 memantine, 118–119
 N-methyl-D-aspartate receptor
 antagonists
 for dementia following stroke, 3
 for VCI, 118–119
 methylprednisolone
 for HE, 125–126
 for NMDA-receptor antibody positive
 limbic encephalitis, 121–122
 microscopic examination
 alexia without agraphia, 79–80
 GRN mutations, 51–52
 MAPT mutations, 46–48
 microtubule-associated protein tau
 (MAPT) mutation, 33
 case history, 44
 clinical course, 45–46
 clinical examination, 45
 diagnosis, 45–46
 discussion, 46–48
 family history, 44
 follow-up, 46
- genetic testing, 46
 investigations, 45
 neuropathology gross description and
 microscopic examination, 46–48
 past medical history, 44
 social history, 45
 motor neuron disease (MND), FTLT
 with, 36–41
 MRI. *See* magnetic resonance imaging
 MSA. *See* multiple system atrophy
 MSA-P. *See* multiple system atrophy
 with predominant parkinsonism
 multiple system atrophy (MSA), 171
 multiple system atrophy with
 predominant parkinsonism
 (MSA-P)
 clinical history and main complaint,
 101
 diagnosis, 102
 discussion and take-home message,
 102
 evolution, 102
 examination, 101–102
 family history, 101
 general history, 101
 laboratory studies, 102
 multiple system tauopathy with
 dementia, 33
 case history, 44
 clinical course, 45–46
 clinical examination, 45
 diagnosis, 45–46
 discussion, 46–48
 family history, 44
 follow-up, 46
 genetic testing, 46
 investigations, 45
 neuropathology gross description
 and microscopic examination,
 46–48
 past medical history, 44
 social history, 45
 myoclonus, 62
- NAE. *See* amino (NH₂)-terminal of α -
 enolase
 naming, in non-fluent/agrammatic
 PPA, 69
 National Institute on Aging and
 Alzheimer's Association (NIA-
 AA) diagnostic criteria, 27–29
 neural compensation, 20
 neurodegeneration
 biomarkers of, 2–5
 without clinical manifestation, 18–21
 neurofibrillary tangle predominant
 dementia (NFTPD)
 clinical history, 22
 complaint, 22

Index

- neurofibrillary tangle predominant dementia (NFTPD) (cont.)
 diagnosis, 23
 discussion and take-home messages, 23–24
 examination, 14, 23
 family history, 23
 follow-up, 23
 general history, 22
 neurofibrillary tangles (NFT)
 biomarkers of, 4
 without clinical manifestation, 18–21
 neuroleptics, in LBD, 96–97
 neurological examination
 ADAD, 10
 ALS-FTD, 36–37
 bvFTD, 30
 CJD, 132
 GRN mutations, 50
 IBGC, 149
 LBD, 96, 98
 MAPT mutations, 45
 MSA-P, 101
 PD, 109
 PPA-A, 68
 PSP, 92, 94
 Wilson's disease, 105–106
 neuropsychological evaluation
 ADAD, 10–11
 alexia without agraphia, 78–79
 ALS-FTD, 37–38
 bvFTD, 30–31
 CHMP2B mutations, 54–57
 CJD, 132
 GRN mutations, 50
 iNPH, 128
 logopenic PPA, 74–75, 77
 MAPT mutations, 45
 MSA-P, 102
 non-fluent/agrammatic PPA, 68, 72
 PCA, 59, 61
 PCA with logopenia, 64
 RtvFTD, 140
 semantic PPA, 84–85
 NFT. *See* neurofibrillary tangles
 NFTPD. *See* neurofibrillary tangle predominant dementia
 NIA-AA diagnostic criteria. *See* National Institute on Aging and Alzheimer's Association diagnostic criteria
 Niemann-Pick disease (NP), 172. *See also* Pick's disease
 NMDA-receptor antibody positive limbic encephalitis
 case management and disease course, 121–122
 clinical history and main complaint, 120
 CSF analysis, 120–122
 discussion, 121–123
 imaging and EEG, 120–121
 medical history, 118
 non-fluent/agrammatic PPA (PPA-A)
 clinical history and main complaint, 68
 diagnosis, 70
 discussion, 71–73
 family history, 68
 follow-up, 70–71
 general history, 68
 neuroimaging findings and biomarker analysis, 70–73
 neurological exam, 68
 neuropsychological evaluation, 68, 72
 speech and language assessment, 68–70
 NP. *See* Niemann-Pick disease
 olanzapine, 121
 oral discourse production, in non-fluent/agrammatic PPA, 69–70
 orthostatic hypotension, in MSA-P, 101–103
 paraneoplastic limbic encephalitis
 case management and disease course, 121–122
 clinical history and main complaint, 120
 CSF analysis, 120–122
 discussion, 121–123
 imaging and EEG, 120–121
 medical history, 120
 Parkinson disease (PD)
 clinical history and main complaint, 109
 dementia and cognitive impairment in, 97, 110–111
 diagnosis, 110
 diagnostic criteria, 164–165
 discussion and take-home messages, 110–111
 family history, 109
 follow-up, 110
 general examination, 109
 general history, 109
 iNPH compared with, 129–131
 LBD compared with, 97
 special studies, 110
 parkinsonism
 in LBD, 96–97
 in MSA-P, 101–103
 PART. *See* primary age-related tauopathy
 passive reserve, 20
 PCA. *See* posterior cortical atrophy
 PD. *See* Parkinson disease
 D-penicillamine, 106, 108
 PET. *See* positron emission tomography
 phosphorylated tau, 4
 Pick's disease
 autopsy, 79–80
 clinical history and main complaint, 78
 diagnosis, 78
 diagnostic criteria, 172
 discussion, 80–81
 examination, 78
 family history, 78
 follow-up, 78–79
 general history, 78
 pimavanserin, 111
 plasmapheresis, for NMDA-receptor antibody positive limbic encephalitis, 121–122
 positron emission tomography (PET)
 ADAD, 10–12
 ARIA in AD, 26–28
 Benson's Syndrome, 62
 C9orf72 mutations, 37–38, 40–41
 CHMP2B mutations, 54–56
 cognitive reserve, 18–21
 dementia following stroke, 114
 diagnostic workup using, 2–4
 IBGC, 149–151
 LBD, 96–99
 MSA-P, 103
 NFTPD and PART, 22–24
 non-fluent/agrammatic PPA, 70–73
 PCA with logopenia, 64–66
 PSP, 93, 110
 typical AD, 14–16
 posterior cortical atrophy (PCA)
 clinical history and main complaint, 59
 diagnosis, 60
 diagnostic criteria, 163
 discussion, 61
 examination, 59
 family history, 59
 follow-up, 60–61
 general history, 59
 key features, 61–62, 65–66
 special studies, 59–61
 take-home messages, 62
 posterior cortical atrophy (PCA) with logopenia
 case history, 64
 cognitive examination, 64
 diagnosis, 65
 discussion, 65–67
 follow-up, 65
 paraclinical workup, 64–65
 physical examination, 64

- post-stroke dementia
 clinical history and main complaint, 112
 diagnosis, 113
 discussion, 113–115
 examination, 112
 family history, 112
 follow-up, 113
 general history, 112
 special studies, 112–113
- postural instability, in PSP, 92–93
- PPA. *See* primary progressive aphasia
- PPA-A. *See* non-fluent/agrammatic PPA
- PPA-L. *See* logopenic PPA
- PPAOS. *See* primary progressive AOS
- PPA-S. *See* semantic PPA
- prednisolone
 for HE, 125–126
 for NMDA-receptor antibody positive limbic encephalitis, 121–122
- presenilin 1 (*PSI*) mutations
 clinical history and main complaint, 10
 diagnosis, 11
 discussion and take-home messages, 11–12
 examination, 10
 family history, 10
 follow-up, 11
 general history, 10
 laboratorial assessment and imaging, 10–11
- primary age-related tauopathy (PART)
 clinical history, 22
 complaint, 22
 diagnosis, 23
 discussion and take-home messages, 23–24
 examination, 14, 23
 family history, 23
 follow-up, 23
 general history, 22
- primary familial brain calcification. *See* idiopathic basal ganglia calcification
- primary progressive aphasia (PPA)
 diagnostic criteria, 160–161
 logopenic variant, 66, 71–72, 74–77
 non-fluent/agrammatic variant, 68–73
 semantic variant, 71–72, 84–91, 140–144
- prion disease
 CJD, 132–135, 139, 153–154
 PRNP mutation, 10–12
- progranulin (*GRN*) mutation, 33
 case history, 49
 clinical course, 50–51
- clinical examination, 50
 diagnosis, 50–52
 discussion, 52
 family history, 49
 genetic testing, 52
 investigations, 50
 neuropathology gross description and microscopic examination, 51–52
 past medical history, 49
 social history, 49–50
- progressive supranuclear palsy (PSP)
 clinical history and main complaint, 92
 diagnosis, 92–93
 diagnostic criteria, 156–159
 discussion and take-home messages, 93–94
 family history, 92
 follow-up, 93
 general examination, 92
 general history, 92
 special studies, 110
 variants of, 93–94
- PSI* mutations. *See* presenilin 1 mutations
- PSG. *See* polysomnography
- PSP. *See* progressive supranuclear palsy
- psychiatric disorders
 NMDA-receptor antibody positive limbic encephalitis compared with, 120–123
- pure alexia. *See* alexia without agraphia
- quetiapine, 109–111
- randomized clinical trials (RCT), 15
- rasagiline, 110
- RCT. *See* randomized clinical trials
- reading, in non-fluent/agrammatic PPA, 69–70
- reading deficits. *See* alexia without agraphia
- repetition, in non-fluent/agrammatic PPA, 69
- right temporal variant FTD (RtvFTD)
 case, 140–141
 diagnosis, 140
 discussion, 140–144
- riluzole, 41
- risperidone, 31–32
- rivastigmine
 for LBD, 97–98
 for PD, 110–111
 for VCI, 118
- RtvFTD. *See* right temporal variant FTD
- safety MRIs, 26–28
- schizophrenic psychosis, 120–123
- sCJD. *See* sporadic CJD
- selective serotonin reuptake inhibitors (SSRIs), for ALS-FTD, 41
- semantic PPA (PPA-S), 71–72
 clinical history and main complaint, 84
 discussion, 86–88
 examination, 84–85
 neuroimaging findings, 85–86
 RtvFTD compared with, 140–144
- semantic PPA (PPA-S) with artistic creativity
 clinical history and main complaint, 89
 diagnostic workup, 89
 discussion, 89–91
 examination, 89
 follow-up, 89–90
- semantic priming effect, 87
- sentence comprehension, in non-fluent/agrammatic PPA, 69–70, 72
- shunt operation, 131
- simultanagnosia, 62, 66
- single photon emission computed tomography (SPECT), 3–4
- CJD, 132
- HE, 125
- PCA, 59–60
- RtvFTD, 140, 143–144
- SLC20A2* mutations, 149–151
- small vessel CVD, 116, 118
- spastic paresis, AD with, 11–12
- SPECT. *See* single photon emission computed tomography
- speech and language assessment
 CJD, 132
 logopenic PPA, 75
 non-fluent/agrammatic PPA, 68–70
 semantic PPA, 84–85
- speech apraxia. *See* apraxia of speech
- sporadic CJD (sCJD), 133
- SREAT. *See* steroid-responsive encephalopathy associated with autoimmune thyroiditis
- SSRIs. *See* selective serotonin reuptake inhibitors
- steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), 125
- stroke, dementia following. *See* post-stroke dementia
- subcortical vascular encephalopathy (SVE), 129–131
- supranuclear gaze palsy, 92–94
- SVE. *See* subcortical vascular encephalopathy
- synucleinopathies
 LBD, 96–99, 162
 MSA-P, 101–103
 PD, 97, 109–111, 129–131, 164–165

Index

- tap test, 129
- TARDBP gene, 33
- tau pathology
 - biomarkers of, 2–5
 - without clinical manifestation, 18–21
 - in *MAPT* mutation, 44–48
 - in NFTPD and PART, 23–24
 - in Pick’s disease, 79–80
 - in RtvFTD, 143
 - in typical AD, 16
- tau PET scan
 - ARIA in AD, 26–28
 - cognitive reserve, 18–21
 - diagnostic workup using, 2, 4
 - NFTPD and PART, 22–24
 - typical AD, 15–16
- TDP-43. *See* transactive response DNA binding protein 43 kDa
- telegraphic speech, 69
- temporal variant FTD. *See* semantic PPA
- teratoma, behavioral changes and cognitive symptoms in, 120, 122
- TG antibodies. *See* anti-thyroglobulin antibodies
- total tau protein, 4
- TPO antibodies. *See* anti-thyroid peroxidase antibodies
- transactive response DNA binding protein 43 kDa (TDP-43)
 - in bvFTD, 33
 - in *C9orf72* mutations, 39
 - in *GRN* mutations, 49–52
 - in RtvFTD, 143
 - in semantic PPA, 88
- trazodone, 31–33
- tremor
 - in PD, 109–110
 - in Wilson’s disease, 105, 107–108
- trientine, 106, 108
- typical AD
 - case history, 14
 - clinical course, 14–15
 - clinical diagnosis, 14–15
 - clinical investigations, 14–15
 - discussion, 15–16
 - family history, 14
 - initial clinical examination, 14
 - medical history, 14
 - research investigations, 15–16
 - social history, 14
- urinary incontinence, in iNPH, 127–128
- urogenital dysfunction, in MSA-P with, 102–103
- VaD. *See* vascular cognitive impairment
- valosin-containing protein (VCP) gene, 33
- vascular cognitive disorder (VCD), 113–114
- vascular cognitive impairment (VCI, vascular dementia, VaD)
 - AD concomitant with, 116–119
 - case presentation, 116
 - clinical presentation of, 117
 - cognitive profiles of, 117
 - CVD evaluation in, 117–118
 - diagnostic criteria for, 114, 116–117, 170
 - discussion, 116–119
 - management of, 118–119
 - small vessel CVD with, 116, 118
 - spectrum of, 113–114
 - after stroke, 112–115
 - vascular pathology of, 117
- VCD. *See* vascular cognitive disorder
- VCI. *See* vascular cognitive impairment
- VCP gene. *See* valosin-containing protein gene
- venlafaxine, 41
- verbal fluency, in non-fluent/agrammatic PPA, 69
- vertical ocular saccades, 11, 92, 94
- visual disturbances
 - in Benson’s Syndrome, 61–62
 - in PCA with logopenia, 65–67
- visual hallucinations
 - in LBD, 96–99
 - in PD, 109–111
- white matter hyperintensities
 - diagnostic workup using, 3
 - in VCI, 116, 118
- Wilson’s disease
 - clinical history and main complaint, 105
 - discussion, 107
 - examination, 105–106
 - laboratory studies and imaging findings, 106–107
 - treatment, 106, 108
- writing, in non-fluent/agrammatic PPA, 69–70
- young-onset dementia, 1–5. *See also* autosomal dominant AD
- zinc, for Wilson’s disease, 106, 108